These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 7851625)

  • 1. [A five-year follow-up of two different 131I treatment methods for Graves' disease and the factors affecting the outcome].
    Yoshimoto M; Iino S; Yoshimura H; Ishikawa N; Momotani N; Hamada N; Ito K
    Nihon Naibunpi Gakkai Zasshi; 1994 Nov; 70(9):995-1006. PubMed ID: 7851625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The outcome of adjusted accumulation dose of treatment of Graves' disease].
    Gomi Y; Hamada N; Yoshimura H; Ishikawa N; Momotani N; Ito K; Inoue T; Suzuki S
    Kaku Igaku; 1997 Dec; 34(12):1131-8. PubMed ID: 9494335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow-up studies on iodine-131 treatment of hyperthyroid Graves' disease based on the measurement of thyroid volume by ultrasonography.
    Tsuruta M; Nagayama Y; Yokoyama N; Izumi M; Nagataki S
    Ann Nucl Med; 1993 Aug; 7(3):193-7. PubMed ID: 8217496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative evaluation of two fixed doses of 185 and 370 MBq 131I, for the treatment of Graves' disease resistant to antithyroid drugs.
    Esfahani AF; Kakhki VR; Fallahi B; Eftekhari M; Beiki D; Saghari M; Takavar A
    Hell J Nucl Med; 2005; 8(3):158-61. PubMed ID: 16390021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The outcome of treatment with adjusted dose of 131I to thyroid weight for Graves' disease by estimation of effective half life using a single radioiodine uptake measurement].
    Gomi Y; Watanabe M; Yoshimura H; Ishikawa N; Momotani N; Ito K; Inoue T; Ito K; Suzuki S
    Kaku Igaku; 2000 Mar; 37(2):109-14. PubMed ID: 10783569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term carbimazole intake does not affect success rate of radioactive 131Iodine in treatment of Graves' hyperthyroidism.
    El Refaei SM; Shawkat W
    Nucl Med Commun; 2008 Jul; 29(7):642-8. PubMed ID: 18528187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radioiodine (131I) therapy of Graves' disease: use of the new high resolutional ultrasonic scanner for the determination of the accurate weight of the thyroid gland.
    Nagayama Y; Ashizawa K; Matsuo K; Inoue S; Harakawa S; Hirayu H; Yamashita S; Izumi M; Nagataki S
    Endocrinol Jpn; 1989 Jun; 36(3):359-65. PubMed ID: 2684619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calculation of the radioiodine dose for the treatment of Graves' hyperthyroidism: is more than seven-thousand rad target dose necessary?
    Bajnok L; Mezosi E; Nagy E; Szabo J; Sztojka I; Varga J; Galuska L; Leovey A
    Thyroid; 1999 Sep; 9(9):865-9. PubMed ID: 10524564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antithyroid drugs inhibit radioiodine-induced increases in thyroid autoantibodies in hyperthyroid Graves' disease.
    Nakazato N; Yoshida K; Mori K; Kiso Y; Sayama N; Tani JI; Nakagawa Y; Ito S
    Thyroid; 1999 Aug; 9(8):775-9. PubMed ID: 10482369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One-year follow-up of Graves' disease treatment by four different protocols of radioiodine administration.
    Calegaro JU; De Freitas Gomes E; Bae SH; Ulyssea R; Casulari LA
    Panminerva Med; 2000 Dec; 42(4):241-5. PubMed ID: 11294085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage.
    Chiovato L; Fiore E; Vitti P; Rocchi R; Rago T; Dokic D; Latrofa F; Mammoli C; Lippi F; Ceccarelli C; Pinchera A
    J Clin Endocrinol Metab; 1998 Jan; 83(1):40-6. PubMed ID: 9435414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pattern of recovery of the hypothalamic-pituitary-thyroid axis following radioactive iodine therapy in patients with Graves' disease.
    Uy HL; Reasner CA; Samuels MH
    Am J Med; 1995 Aug; 99(2):173-9. PubMed ID: 7625422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ultrasonographic thyroid volume as a reliable prognostic index of radioiodine-131 treatment outcome in Graves' disease hyperthyroidism.
    Gómez-Arnaiz N; Andía E; Gumà A; Abós R; Soler J; Gómez JM
    Horm Metab Res; 2003 Aug; 35(8):492-7. PubMed ID: 12953167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thyrotropin receptor antibody activities significantly correlate with the outcome of radioiodine (131I) therapy for hyperthyroid Graves' disease.
    Kaise K; Kaise N; Yoshida K; Fukazawa H; Mori K; Yamamoto M; Sakurada T; Saito S; Yoshinaga K
    Endocrinol Jpn; 1991 Aug; 38(4):429-33. PubMed ID: 1687028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of the optimal minimum radioiodine dose in patients with Graves' disease: a clinical outcome study.
    Howarth D; Epstein M; Lan L; Tan P; Booker J
    Eur J Nucl Med; 2001 Oct; 28(10):1489-95. PubMed ID: 11685491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The development of transient hypothyroidism after iodine-131 treatment in hyperthyroid patients with Graves' disease: prevalence, mechanism and prognosis.
    Aizawa Y; Yoshida K; Kaise N; Fukazawa H; Kiso Y; Sayama N; Hori H; Abe K
    Clin Endocrinol (Oxf); 1997 Jan; 46(1):1-5. PubMed ID: 9059550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements.
    Berg GE; Michanek AM; Holmberg EC; Fink M
    J Nucl Med; 1996 Feb; 37(2):228-32. PubMed ID: 8667049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A predictive mathematical model for the calculation of the final mass of Graves' disease thyroids treated with 131I.
    Traino AC; Di Martino F; Grosso M; Monzani F; Dardano A; Caraccio N; Mariani G; Lazzeri M
    Phys Med Biol; 2005 May; 50(9):2181-91. PubMed ID: 15843745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Compensated low-dose 131I therapy of Graves' disease.
    Roudebush CP; Hoye KE; DeGroot LJ
    Ann Intern Med; 1977 Oct; 87(4):441-3. PubMed ID: 578665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of RA 131I treatment protocols for Graves' disease.
    DeGroot LJ; Mangklabruks A; McCormick M
    J Endocrinol Invest; 1990 Feb; 13(2):111-8. PubMed ID: 2329258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.